Syndax Pharmaceuticals, Inc. (SNDX) Reaches $9.19 After 5.00% Down Move; Access National Has 1.5 Sentiment

January 14, 2018 - By wolcottdaily

The stock of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a huge mover today! The stock decreased 3.26% or $0.31 during the last trading session, reaching $9.19. About 222,443 shares traded. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has risen 7.09% since January 14, 2017 and is uptrending. It has underperformed by 9.61% the S&P500.The move comes after 7 months negative chart setup for the $224.14 million company. It was reported on Jan, 14 by Barchart.com. We have $8.73 PT which if reached, will make NASDAQ:SNDX worth $11.21M less.

Access National Corporation operates as a bank holding firm for Access National Bank that provides credit, deposit, mortgage, and wealth management services to small and medium sized businesses, professionals, and associated individuals primarily in the greater Washington, D.C. The company has market cap of $594.77 million. Metropolitan Area. It has a 27.85 P/E ratio. The firm operates through three divisions: Commercial Banking, Mortgage Banking, and Wealth Management.

Ratings analysis reveals 67% of Access Natl’s analysts are positive. Out of 3 Wall Street analysts rating Access Natl, 2 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $21.5 while the high is $29.0. The stock’s average target of $29 is -0.28% below today’s ($29.08) share price. ANCX was included in 4 notes of analysts from August 25, 2015. Maxim Group initiated Access National Corporation (NASDAQ:ANCX) on Tuesday, August 25 with “Buy” rating. As per Tuesday, August 25, the company rating was upgraded by Raymond James. The rating was maintained by Maxim Group with “Buy” on Thursday, October 20. FBR Capital upgraded the stock to “Outperform” rating in Tuesday, October 25 report.

Analysts await Access National Corporation (NASDAQ:ANCX) to report earnings on January, 19. They expect $0.41 EPS, up 46.43% or $0.13 from last year’s $0.28 per share. ANCX’s profit will be $8.39 million for 17.73 P/E if the $0.41 EPS becomes a reality. After $0.42 actual EPS reported by Access National Corporation for the previous quarter, Wall Street now forecasts -2.38% negative EPS growth.

The stock increased 0.35% or $0.1 during the last trading session, reaching $29.08. About 28,892 shares traded or 5.41% up from the average. Access National Corporation (ANCX) has risen 46.56% since January 14, 2017 and is uptrending. It has outperformed by 29.86% the S&P500.

Motley Fool Asset Management Llc holds 0.52% of its portfolio in Access National Corporation for 90,529 shares. Buckingham Asset Management Llc owns 60,311 shares or 0.41% of their US portfolio. Moreover, Penn Capital Management Co Inc has 0.3% invested in the company for 143,677 shares. The Virginia-based Motley Fool Wealth Management Llc has invested 0.28% in the stock. Montgomery Investment Management Inc, a Maryland-based fund reported 11,683 shares.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company has market cap of $224.14 million. The companyÂ’s lead product candidate is Entinostat, which is in Phase III clinical trial for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer; and Phase 2b clinical trial. It currently has negative earnings. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>